Updated guideline redefines HF stages, emphasizes prevention, new treatments

WASHINGTON — A joint guideline from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America redefines HF stages to focus on prevention and recommends HF treatment with SGLT2 inhibitors.
The new guideline, presented at the American College of Cardiology Scientific Session, is the first full revision since 2013, replacing the ACC Foundation/AHA Guideline for the Management of Heart Failure and the 2017 ACC/AHA/HFSA Focused Update of the 2013 guideline.
The guideline was simultaneously published in the Journal of the American College of

WASHINGTON — A joint guideline from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America redefines HF stages to focus on prevention and recommends HF treatment with SGLT2 inhibitors.
The new guideline, presented at the American College of Cardiology Scientific Session, is the first full revision since 2013, replacing the ACC Foundation/AHA Guideline for the Management of Heart Failure and the 2017 ACC/AHA/HFSA Focused Update of the 2013 guideline.
The guideline was simultaneously published in the Journal of the American College of